医药外包概念股全线走低金斯瑞生物科技(01548)跌7.43%、药明生物(02269)跌7.39%

金吾财讯

Jun 08

金吾财讯 | 医药外包概念股全线走低，金斯瑞生物科技(01548)跌7.43%，药明生物(02269)跌7.39%，方达控股(01521)跌7.27%，康龙化成(03759)跌6.31%，泰格医药(03347)跌6.25%，凯莱英(06821)跌6.10%，维亚生物(01873)跌5.79%，昭衍新药(06127)跌4.94%，药明康德(02359)跌3.94%。中邮证券表示，2026年第一季度，海外CXO行业整体呈现分化复苏格局，全球生物制药融资环境出现实质性改善，带动需求逐步回暖，但早期初创企业资金压力仍未完全缓解，不同细分赛道、不同规模企业的表现存在差异，行业结构性分化特征进一步凸显。整体看，CDMO行业业绩稳定，临床CRO表观有所恢复但订单有波动，临床前CRO复苏节奏相对滞后。国金证券表示，CXO行业已完整经历一轮产业周期，当下行业景气度上行信号明确。目前，随着外部压力缓释、全球投融资回暖，国内BD持续升温，行业已进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2641105779"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641105779\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641105779?lang=en_US&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","is_english":false,"pubTime":"2026-06-08 13:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641105779","market":"other","top_or_hot":-1,"title":"医药外包概念股全线走低 金斯瑞生物科技(01548)跌7.43%、药明生物(02269)跌7.39%","media":"金吾财讯","content":"<html><body><p>金吾财讯 | 医药外包概念股全线走低，<a href=\"https://laohu8.com/S/01548\">金斯瑞生物科技</a>(01548)跌7.43%，<a href=\"https://laohu8.com/S/02269\">药明生物</a>(02269)跌7.39%，<a href=\"https://laohu8.com/S/01521\">方达控股</a>(01521)跌7.27%，<a href=\"https://laohu8.com/S/300759\">康龙化成</a>(03759)跌6.31%，<a href=\"https://laohu8.com/S/300347\">泰格医药</a>(03347)跌6.25%，<a href=\"https://laohu8.com/S/002821\">凯莱英</a>(06821)跌6.10%，<a href=\"https://laohu8.com/S/01873\">维亚生物</a>(01873)跌5.79%，<a href=\"https://laohu8.com/S/603127\">昭衍新药</a>(06127)跌4.94%，<a href=\"https://laohu8.com/S/603259\">药明康德</a>(02359)跌3.94%。<a href=\"https://laohu8.com/S/688648\">中邮</a>证券表示，2026年第一季度，海外CXO行业整体呈现分化复苏格局，全球生物制药融资环境出现实质性改善，带动需求逐步回暖，但早期初创企业资金压力仍未完全缓解，不同细分赛道、不同规模企业的表现存在差异，行业结构性分化特征进一步凸显。整体看，CDMO行业业绩稳定，临床CRO表观有所恢复但订单有波动，临床前CRO复苏节奏相对滞后。<a href=\"https://laohu8.com/S/600109\">国金证券</a>表示，CXO行业已完整经历一轮产业周期，当下行业景气度上行信号明确。目前，随着外部压力缓释、全球投融资回暖，国内BD持续升温，行业已进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药外包概念股全线走低 金斯瑞生物科技(01548)跌7.43%、药明生物(02269)跌7.39%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药外包概念股全线走低 金斯瑞生物科技(01548)跌7.43%、药明生物(02269)跌7.39%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">金吾财讯 </p>\n<p class=\"h-time\">2026-06-08 13:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>金吾财讯 | 医药外包概念股全线走低，<a href=\"https://laohu8.com/S/01548\">金斯瑞生物科技</a>(01548)跌7.43%，<a href=\"https://laohu8.com/S/02269\">药明生物</a>(02269)跌7.39%，<a href=\"https://laohu8.com/S/01521\">方达控股</a>(01521)跌7.27%，<a href=\"https://laohu8.com/S/300759\">康龙化成</a>(03759)跌6.31%，<a href=\"https://laohu8.com/S/300347\">泰格医药</a>(03347)跌6.25%，<a href=\"https://laohu8.com/S/002821\">凯莱英</a>(06821)跌6.10%，<a href=\"https://laohu8.com/S/01873\">维亚生物</a>(01873)跌5.79%，<a href=\"https://laohu8.com/S/603127\">昭衍新药</a>(06127)跌4.94%，<a href=\"https://laohu8.com/S/603259\">药明康德</a>(02359)跌3.94%。<a href=\"https://laohu8.com/S/688648\">中邮</a>证券表示，2026年第一季度，海外CXO行业整体呈现分化复苏格局，全球生物制药融资环境出现实质性改善，带动需求逐步回暖，但早期初创企业资金压力仍未完全缓解，不同细分赛道、不同规模企业的表现存在差异，行业结构性分化特征进一步凸显。整体看，CDMO行业业绩稳定，临床CRO表观有所恢复但订单有波动，临床前CRO复苏节奏相对滞后。<a href=\"https://laohu8.com/S/600109\">国金证券</a>表示，CXO行业已完整经历一轮产业周期，当下行业景气度上行信号明确。目前，随着外部压力缓释、全球投融资回暖，国内BD持续升温，行业已进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0307460666.USD","symbol_name":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","start_time":0,"source_url":"1983281","article_id":"2641105779","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641105779","pubTimestamp":1780897412,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"中邮证券表示，2026年第一季度，海外CXO行业整体呈现分化复苏格局，全球生物制药融资环境出现实质性改善，带动需求逐步回暖，但早期初创企业资金压力仍未完全缓解，不同细分赛道、不同规模企业的表现存在差异，行业结构性分化特征进一步凸显。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","02269":"药明生物","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1521":"挪威政府全球养老基金持仓","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","06821":"凯莱英","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1720050803.USD":"安联全方位中国股票基金","BK1589":"北水核心资产","01873":"维亚生物","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","BK1141":"生命科学工具和服务","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","01548":"金斯瑞生物科技","BK1191":"制药","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","09939":"开拓药业-B","01521":"方达控股","BK1574":"生物医药B类股","LU0051755006.USD":"摩根大通中国A (dist)","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","06127":"昭衍新药","03347":"泰格医药","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","BK1515":"抗疫概念","02359":"药明康德","03759":"康龙化成","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC"},"translate_title":"Pharmaceutical outsourcing concept stocks fell across the board GenScript Biotechnology (01548) fell 7.43%, WuXi Biologics (02269) fell 7.39%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"01873":0.9,"03347":0.9,"03759":0.9,"09939":1.5,"01521":0.9,"01548":1.5,"02359":0.9,"02269":1.5,"06127":0.9,"06821":0.9},"content_text":"金吾财讯 | 医药外包概念股全线走低，金斯瑞生物科技(01548)跌7.43%，药明生物(02269)跌7.39%，方达控股(01521)跌7.27%，康龙化成(03759)跌6.31%，泰格医药(03347)跌6.25%，凯莱英(06821)跌6.10%，维亚生物(01873)跌5.79%，昭衍新药(06127)跌4.94%，药明康德(02359)跌3.94%。中邮证券表示，2026年第一季度，海外CXO行业整体呈现分化复苏格局，全球生物制药融资环境出现实质性改善，带动需求逐步回暖，但早期初创企业资金压力仍未完全缓解，不同细分赛道、不同规模企业的表现存在差异，行业结构性分化特征进一步凸显。整体看，CDMO行业业绩稳定，临床CRO表观有所恢复但订单有波动，临床前CRO复苏节奏相对滞后。国金证券表示，CXO行业已完整经历一轮产业周期，当下行业景气度上行信号明确。目前，随着外部压力缓释、全球投融资回暖，国内BD持续升温，行业已进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}